• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Gastrointestinal Tract Cancer - Pipeline Review, H2 2012 Product Image

Gastrointestinal Tract Cancer - Pipeline Review, H2 2012

  • ID: 2245278
  • September 2012
  • 498 pages
  • Global Markets Direct

Gastrointestinal Tract Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Gastrointestinal Tract Cancer - Pipeline Review, Global Markets Direct’s, 'Gastrointestinal Tract Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Tract Cancer. Gastrointestinal Tract Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic READ MORE >

2
List of Tables 15
List of Figures 22
Introduction 23
REPORT COVERAGE 23
Gastrointestinal Tract Cancer Overview 24
Therapeutics Development 25
An Overview of Pipeline Products for Gastrointestinal Tract Cancer 25
Gastrointestinal Tract Cancer Therapeutics under Development by Companies 27
Gastrointestinal Tract Cancer Therapeutics under Investigation by Universities/Institutes 41
Late Stage Products 60
Comparative Analysis 60
Mid Clinical Stage Products 61
Comparative Analysis 61
Early Clinical Stage Products 62
Comparative Analysis 62
Discovery and Pre-Clinical Stage Products 63
Comparative Analysis 63
Gastrointestinal Tract Cancer Therapeutics – Products under Development by Companies 64
Gastrointestinal Tract Cancer Therapeutics – Products under Investigation by Universities/Institutes 81
Companies Involved in Gastrointestinal Tract Cancer Therapeutics Development 129
Bristol-Myers Squibb Company 129
Johnson & Johnson 130
F. Hoffmann-La Roche Ltd. 131
Shionogi & Co., Ltd. 132
Amgen Inc. 133
Sanofi-Aventis 134
AstraZeneca PLC 135
Eli Lilly and Company 136
Viralytics Ltd. 137
GlaxoSmithKline plc 138
Tekmira Pharmaceuticals Corp. 139
Genentech, Inc. 140
Nektar Therapeutics 141
Inovio Biomedical Corporation 142
Bavarian Nordic A/S 143
Daiichi Sankyo Company, Ltd 144
AbGenomics International, Inc. 145
Oxford BioMedica plc 146
Infinity Pharmaceuticals, Inc. 147
YM BioSciences Inc. 148
FibroGen, Inc. 149
Light Sciences Oncology, Inc. 150
Panacea Pharmaceuticals, Inc. 151
Piramal Healthcare Limited 152
MediGene AG 153
BioSante Pharmaceuticals, Inc. 154
ZIOPHARM Oncology, Inc. 155
Millennium Pharmaceuticals, Inc. 156
Novartis AG 157
Samyang Corporation 158
Aphios Corporation 159
Astellas Pharma Inc. 160
OSI Pharmaceuticals, Inc. 161
SuperGen, Inc. 162
Taiho Pharmaceutical Co., Ltd. 163
Yakult Honsha Co., Ltd. 164
Zeria Pharmaceutical Co Ltd 165
Cell Therapeutics, Inc. 166
Exelixis, Inc. 167
Aduro BioTech 168
Incyte Corporation 169
Halozyme Therapeutics 170
Merck KGaA 171
Access Pharmaceuticals, Inc. 172
Advaxis, Inc. 173
Neogenix Oncology Corporation 174
EntreMed, Inc. 175
Momenta Pharmaceuticals, Inc. 176
Anavex Life Sciences Corp. 177
ValiRx Plc 178
ImmunoCellular Therapeutics, Ltd. 179
IMMUNOMEDICS, INC 180
Karo Bio 181
Lorus Therapeutics Inc 182
Transgene Biotek Ltd 206
Rexahn Pharmaceuticals, Inc. 207
MabVax Therapeutics, Inc. 208
Morphotek, Inc. 209
D-Pharm Ltd. 210
Antisense Pharma GmbH 211
Cornerstone Pharmaceuticals, Inc. 241
Pharminox Limited 242
PhytoCeutica, Inc. 243
Myriad Pharmaceuticals, Inc. 244
KangLaiTe USA 245
NovaLead Pharma Pvt. Ltd. 246
Esperance Pharmaceuticals, Inc. 247
Omeros Corporation 248
Transtech Pharma, Inc. 249
Welichem Biotech Inc. 250
Oncolys BioPharma Inc. 251
Globeimmune, Inc. 252
NewLink Genetics Corporation 253
Tragara Pharmaceuticals, Inc. 254
Cellceutix Corporation 255
PharmaMar, S.A. 256
Quintessence Biosciences, Inc. 257
Tigris Pharmaceuticals, Inc. 258
Lipopharma 259
Nereus Pharmaceuticals, Inc. 260
AVEO Pharmaceuticals, Inc. 261
Kringle Pharma, Inc. 262
Medisyn Technologies, Inc. 263
Keystone Nano, Inc. 264
Perseus Proteomics, Inc. 265
Pique Therapeutics 266
Cancer Therapeutics CRC Pty Ltd 267
Eleison Pharmaceuticals, Inc. 268
Targa Therapeutics Corp. 269
ImmunoFrontier, Inc. 270
NuCana BioMed Limited 271
KAEL-GemVax 272
iCeutica, Inc. 273
Mebiopharm Co., Ltd. 274
Polaris Group 275
Eurofarma 276
DEKK-TEC, Inc. 277
IkerChem S.L. 278
Theradex Systems, Inc. 279
Regulon Inc. 280
TAU Therapeutics, LLC 281
FunZyme BioTechnologies S.A. 282
Epeius Biotechnologies Corporation 283
Oncozyme Pharma Inc. 284
Biotech Pharmaceuticals Co., Ltd. 285
CytomX, LLC. 286
Gastrointestinal Tract Cancer – Therapeutics Assessment 287
Assessment by Monotherapy Products 287
Assessment by Combination Products 288
Assessment by Route of Administration 289
Assessment by Molecule Type 291
Drug Profiles 293
glufosfamide - Drug Profile 293
Product Description 293
Mechanism of Action 293
R&D Progress 293
ramucirumab - Drug Profile 295
Product Description 295
Mechanism of Action 295
R&D Progress 295
GV-1001 - Drug Profile 297
Product Description 297
Mechanism of Action 297
R&D Progress 297
SP-1049C - Drug Profile 299
Product Description 299
Mechanism of Action 299
R&D Progress 299
HyperAcute Pancreas Immunotherapy - Drug Profile 301
Product Description 301
Mechanism of Action 301
R&D Progress 301
Rexin-G - Drug Profile 302
Product Description 302
Mechanism of Action 302
R&D Progress 302
gemcitabine - Drug Profile 304
Product Description 304
Mechanism of Action 304
R&D Progress 304
Gemcitabine + Nab-Paclitaxel1 - Drug Profile 305
Product Description 305
Mechanism of Action 305
R&D Progress 305
Fluorouracil + Radiation Therapy - Drug Profile 306
Product Description 306
Mechanism of Action 306
R&D Progress 306
capecitabine - Drug Profile 308
Product Description 308
Mechanism of Action 308
R&D Progress 308
docetaxel - Drug Profile 309
Product Description 309
Mechanism of Action 309
R&D Progress 309
Capecitabine + Gemcitabine - Drug Profile 310
Product Description 310
Mechanism of Action 310
R&D Progress 310
Gemcitabine + Radiation Therapy - Drug Profile 312
Product Description 312
Mechanism of Action 312
R&D Progress 312
Capecitabine + Cisplatin + Epirubicin + Fluorouracil + Gemcitabine + Radiation Therapy - Drug Profile 314
Product Description 314
Mechanism of Action 314
R&D Progress 315
S-1 + Oxaliplatin - Drug Profile 364
Product Description 364
Mechanism of Action 364
R&D Progress 364
OTS102 + Gemcitabine - Drug Profile 365
Product Description 365
Mechanism of Action 365
R&D Progress 365
gemcitabine - Drug Profile 366
Product Description 366
Mechanism of Action 366
R&D Progress 366
gefitinib - Drug Profile 367
Product Description 367
Mechanism of Action 367
R&D Progress 367
Gemcitabine Hydrochloride + Oxaliplatin - Drug Profile 411
Product Description 411
Mechanism of Action 411
R&D Progress 411
Navelbine + Cisplatin + Radiotherapy - Drug Profile 412
Product Description 412
Mechanism of Action 412
R&D Progress 412
5-Fluorouracil + Cisplatin - Drug Profile 413
Product Description 413
Mechanism of Action 413
R&D Progress 413
uridine triacetate - Drug Profile 414
Product Description 414
Mechanism of Action 414
R&D Progress 414
Trastuzumab + Carboplatin + Paclitaxel - Drug Profile 416
Product Description 416
Mechanism of Action 416
R&D Progress 417
Gemox 85 - Drug Profile 425
Product Description 425
Mechanism of Action 425
R&D Progress 425
Gastrointestinal Tract Cancer Therapeutics – Drug Profile Updates 426
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products 431
Gastrointestinal Tract Cancer Therapeutics - Dormant Products 442
Gastrointestinal Tract Cancer – Product Development Milestones 489
Featured News & Press Releases 489
Aug 29, 2012: Lorus Therapeutics Receives Funding From Government Of Canada For Development Of Cancer Therapy IL-17E 489
Aug 06, 2012: Rexahn Pharma Completes Exploratory Phase I Clinical Study Of RX-3117 489
Jun 28, 2012: Lorus Therapeutics Receives Canadian Patent For New Anticancer Therapy IL-17E 490
Jun 27, 2012: GlobeImmune’s GI-4000 In Combination With Gemcitabine Following Surgery Shows Evidence Of Improvement In Survival In Phase IIb Clinical Trial With Ras Mutation Positive Pancreas Cancer 490
Jun 26, 2012: Merrimack Pharma To Present Data On Network Biology Approach To Therapeutic Development At 2012 AACR Chemical Systems Biology Conference 491
Jun 25, 2012: Peregrine Pharma Completes Patient Enrollment In Phase II Pancreatic Cancer Trial Of Bavituximab In Combination With Gemcitabine 492
Jun 20, 2012: Bayer's New Chemotherapy Drug Found To Be Effective Against Pancreatic Cancer, Study Finds 493
Jun 19, 2012: Addition Of Erlotinib To Bevacizumab Plus Chemoradiotherapy Regimen For Locally Advanced Pancreatic Cancer Is Safe and Tolerable, Study Finds 493
Jun 19, 2012: GDC-0449 In Combination With Gemcitabine Found To Be Effective Against Pancreatic Cancer, Research Finds 494
Jun 19, 2012: NewLink Updates Enrollment Information For Pivotal Phase III HyperAcute Pancreas Immunotherapy Trial 495
Appendix 497
Methodology 497
Coverage 497
Secondary Research 497
Primary Research 497
Expert Panel Validation 497
Contact Us 498
Disclaimer 498

List of Tables
Number of Products Under Development for Gastrointestinal Tract Cancer, H2 2012 25
Products under Development for Gastrointestinal Tract Cancer – Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Development by Companies, H2 2012 (Contd..4) 32
Number of Products under Development by Companies, H2 2012 (Contd..5) 33
Number of Products under Development by Companies, H2 2012 (Contd..6) 34
Number of Products under Development by Companies, H2 2012 (Contd..7) 35
Number of Products under Development by Companies, H2 2012 (Contd..8) 36
Number of Products under Development by Companies, H2 2012 (Contd..9) 37
Number of Products under Development by Companies, H2 2012 (Contd..10) 38
Number of Products under Development by Companies, H2 2012 (Contd..11) 39
Number of Products under Development by Companies, H2 2012 (Contd..12) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 59
Comparative Analysis by Late Stage Development, H2 2012 60
Comparative Analysis by Mid Clinical Stage Development, H2 2012 61
Comparative Analysis by Early Clinical Stage Development, H2 2012 62
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 63
Products under Development by Companies, H2 2012 64
Products under Development by Companies, H2 2012 (Contd..1) 65
Products under Development by Companies, H2 2012 (Contd..2) 66
Products under Development by Companies, H2 2012 (Contd..3) 67
Products under Development by Companies, H2 2012 (Contd..4) 68
Products under Development by Companies, H2 2012 (Contd..5) 69
Products under Development by Companies, H2 2012 (Contd..6) 70
Products under Development by Companies, H2 2012 (Contd..7) 71
Products under Development by Companies, H2 2012 (Contd..8) 72
Products under Development by Companies, H2 2012 (Contd..9) 73
Products under Development by Companies, H2 2012 (Contd..10) 74
Products under Development by Companies, H2 2012 (Contd..11) 75
Products under Development by Companies, H2 2012 (Contd..12) 76
Products under Development by Companies, H2 2012 (Contd..13) 77
Products under Development by Companies, H2 2012 (Contd..14) 78
Products under Development by Companies, H2 2012 (Contd..15) 79
Products under Development by Companies, H2 2012 (Contd..16) 80
Products under Investigation by Universities/Institutes, H2 2012 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 94
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 95
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 96
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 97
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 98
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 99
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 100
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 101
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 102
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 103
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 104
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 105
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 106
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 107
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 108
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 109
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 110
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 111
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 128
Bristol-Myers Squibb Company, H2 2012 129
Johnson & Johnson, H2 2012 130
F. Hoffmann-La Roche Ltd., H2 2012 131
Shionogi & Co., Ltd., H2 2012 132
Amgen Inc., H2 2012 133
Sanofi-Aventis, H2 2012 134
AstraZeneca PLC, H2 2012 135
Eli Lilly and Company, H2 2012 136
Viralytics Ltd., H2 2012 137
GlaxoSmithKline plc, H2 2012 138
Tekmira Pharmaceuticals Corp., H2 2012 139
Genentech, Inc., H2 2012 140
Nektar Therapeutics, H2 2012 141
Inovio Biomedical Corporation, H2 2012 142
Bavarian Nordic A/S, H2 2012 143
Daiichi Sankyo Company, Ltd, H2 2012 144
AbGenomics International, Inc., H2 2012 145
Oxford BioMedica plc, H2 2012 146
Infinity Pharmaceuticals, Inc., H2 2012 147
YM BioSciences Inc., H2 2012 148
FibroGen, Inc., H2 2012 149
Light Sciences Oncology, Inc., H2 2012 150
Panacea Pharmaceuticals, Inc., H2 2012 151
Piramal Healthcare Limited, H2 2012 152
MediGene AG, H2 2012 153
BioSante Pharmaceuticals, Inc., H2 2012 154
ZIOPHARM Oncology, Inc., H2 2012 155
Millennium Pharmaceuticals, Inc., H2 2012 156
Novartis AG, H2 2012 157
Samyang Corporation, H2 2012 158
Aphios Corporation, H2 2012 159
Astellas Pharma Inc., H2 2012 160
OSI Pharmaceuticals, Inc., H2 2012 161
SuperGen, Inc., H2 2012 162
Taiho Pharmaceutical Co., Ltd., H2 2012 163
Yakult Honsha Co., Ltd., H2 2012 164
Zeria Pharmaceutical Co Ltd, H2 2012 165
Cell Therapeutics, Inc., H2 2012 166
Exelixis, Inc., H2 2012 167
Aduro BioTech, H2 2012 168
Incyte Corporation, H2 2012 169
Halozyme Therapeutics, H2 2012 170
Merck KGaA, H2 2012 171
Access Pharmaceuticals, Inc., H2 2012 172
Advaxis, Inc., H2 2012 173
Neogenix Oncology Corporation, H2 2012 174
EntreMed, Inc., H2 2012 175
Momenta Pharmaceuticals, Inc., H2 2012 176
Anavex Life Sciences Corp., H2 2012 177
ValiRx Plc, H2 2012 178
ImmunoCellular Therapeutics, Ltd., H2 2012 179
IMMUNOMEDICS, INC, H2 2012 180
Karo Bio, H2 2012 181
Lorus Therapeutics Inc, H2 2012 182
Marshall Edwards, Inc., H2 2012 183
MethylGene Inc, H2 2012 184
Molecular Insight Pharmaceuticals, Inc., H2 2012 185
Northwest Biotherapeutics, Inc., H2 2012 186
Oncolytics Biotech Inc., H2 2012 187
Peregrine Pharmaceuticals, Inc., H2 2012 188
Critical Outcome Technologies Inc., H2 2012 189
La Jolla Pharmaceutical Company, H2 2012 190
Bionovo, Inc., H2 2012 191
Telik, Inc., H2 2012 192
Champions Biotechnology, Inc., H2 2012 193
Pharmacyclics, Inc., H2 2012 194
ProMetic Life Sciences Inc., H2 2012 195
Green Cross Corporation, H2 2012 196
Innocell Corporation, H2 2012 197
OncoTherapy Science, Inc., H2 2012 198
Quest PharmaTech Inc., H2 2012 199
Threshold Pharmaceuticals, Inc., H2 2012 200
Synta Pharmaceuticals Corp., H2 2012 201
BioAlliance Pharma SA, H2 2012 202
Natco Pharma Limited, H2 2012 203
Sareum Holdings plc, H2 2012 204
Simcere Pharmaceutical Group, H2 2012 205
Transgene Biotek Ltd, H2 2012 206
Rexahn Pharmaceuticals, Inc., H2 2012 207
MabVax Therapeutics, Inc., H2 2012 208
Morphotek, Inc., H2 2012 209
D-Pharm Ltd., H2 2012 210
Antisense Pharma GmbH, H2 2012 211
Avanti Therapeutics, H2 2012 212
Wilex AG, H2 2012 213
Supratek Pharma Inc., H2 2012 214
Immupharma Plc, H2 2012 215
GANYMED Pharmaceuticals AG, H2 2012 216
Philogen S.p.A., H2 2012 217
Multimmune GmbH, H2 2012 218
Nerviano Medical Sciences S.r.l., H2 2012 219
Wellstat Therapeutics Corporation, H2 2012 220
Hutchison MediPharma Limited, H2 2012 221
ERYtech Pharma, H2 2012 222
Advantagene, Inc., H2 2012 223
Provecs Medical GmbH, H2 2012 224
Alethia Biotherapeutics Inc., H2 2012 225
Ascenta Therapeutics, Inc., H2 2012 226
Gene Signal International SA., H2 2012 227
Heat Biologics, Inc., H2 2012 228
MacroGenics, Inc., H2 2012 229
Antyra, Inc., H2 2012 230
TetraLogic Pharmaceuticals, H2 2012 231
Celecure AS, H2 2012 232
Azaya Therapeutics, Inc., H2 2012 233
Merrimack Pharmaceuticals, Inc., H2 2012 234
RESprotect GmbH, H2 2012 235
ProNAi Therapeutics, Inc., H2 2012 236
Jennerex Biotherapeutics, Inc., H2 2012 237
Stemline Therapeutics, Inc., H2 2012 238
Axcentua Pharmaceuticals AB, H2 2012 239
BioCancell Therapeutics, Inc., H2 2012 240
Cornerstone Pharmaceuticals, Inc., H2 2012 241
Pharminox Limited, H2 2012 242
PhytoCeutica, Inc., H2 2012 243
Myriad Pharmaceuticals, Inc., H2 2012 244
KangLaiTe USA, H2 2012 245
NovaLead Pharma Pvt. Ltd., H2 2012 246
Esperance Pharmaceuticals, Inc., H2 2012 247
Omeros Corporation, H2 2012 248
Transtech Pharma, Inc., H2 2012 249
Welichem Biotech Inc., H2 2012 250
Oncolys BioPharma Inc., H2 2012 251
Globeimmune, Inc., H2 2012 252
NewLink Genetics Corporation, H2 2012 253
Tragara Pharmaceuticals, Inc., H2 2012 254
Cellceutix Corporation, H2 2012 255
PharmaMar, S.A., H2 2012 256
Quintessence Biosciences, Inc., H2 2012 257
Tigris Pharmaceuticals, Inc., H2 2012 258
Lipopharma, H2 2012 259
Nereus Pharmaceuticals, Inc., H2 2012 260
AVEO Pharmaceuticals, Inc., H2 2012 261
Kringle Pharma, Inc., H2 2012 262
Medisyn Technologies, Inc., H2 2012 263
Keystone Nano, Inc., H2 2012 264
Perseus Proteomics, Inc., H2 2012 265
Pique Therapeutics, H2 2012 266
Cancer Therapeutics CRC Pty Ltd, H2 2012 267
Eleison Pharmaceuticals, Inc., H2 2012 268
Targa Therapeutics Corp., H2 2012 269
ImmunoFrontier, Inc., H2 2012 270
NuCana BioMed Limited, H2 2012 271
KAEL-GemVax, H2 2012 272
iCeutica, Inc., H2 2012 273
Mebiopharm Co., Ltd., H2 2012 274
Polaris Group, H2 2012 275
Eurofarma, H2 2012 276
DEKK-TEC, Inc., H2 2012 277
IkerChem S.L., H2 2012 278
Theradex Systems, Inc., H2 2012 279
Regulon Inc., H2 2012 280
TAU Therapeutics, LLC, H2 2012 281
FunZyme BioTechnologies S.A., H2 2012 282
Epeius Biotechnologies Corporation, H2 2012 283
Oncozyme Pharma Inc., H2 2012 284
Biotech Pharmaceuticals Co., Ltd., H2 2012 285
CytomX, LLC., H2 2012 286
Assessment by Monotherapy Products, H2 2012 287
Assessment by Combination Products, H2 2012 288
Assessment by Stage and Route of Administration, H2 2012 290
Assessment by Stage and Molecule Type, H2 2012 292
Gastrointestinal Tract Cancer Therapeutics – Drug Profile Updates 426
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products 431
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..1) 432
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..2) 433
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..3) 434
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..4) 435
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..5) 436
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..6) 437
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..7) 438
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..8) 439
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..9) 440
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..10) 441
Gastrointestinal Tract Cancer Therapeutics – Dormant Products 442
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..1) 443
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..2) 444
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..3) 445
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..4) 446
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..5) 447
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..6) 448
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..7) 449
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..8) 450
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..9) 451
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..10) 452
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..11) 453
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..12) 454
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..13) 455
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..14) 456
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..15) 457
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..16) 458
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..17) 459
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..18) 460
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..19) 461
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..20) 462
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..21) 463
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..22) 464
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..23) 465
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..24) 466
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..25) 467
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..26) 468
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..27) 469
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..28) 470
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..29) 471
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..30) 472
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..31) 473
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..32) 474
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..33) 475
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..34) 476
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..35) 477
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..36) 478
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..37) 479
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..38) 480
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..39) 481
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..40) 482
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..41) 483
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..42) 484
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..43) 485
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..44) 486
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..45) 487
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..46) 488

List of Figures
Number of Products under Development for Gastrointestinal Tract Cancer, H2 2012 25
Products under Development for Gastrointestinal Tract Cancer – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 41
Late Stage Products, H2 2012 60
Mid Clinical Stage Products, H2 2012 61
Early Clinical Stage Products, H2 2012 62
Discovery and Pre-Clinical Stage Products, H2 2012 63
Assessment by Monotherapy Products, H2 2012 287
Assessment by Combination Products, H2 2012 288
Assessment by Route of Administration, H2 2012 289
Assessment by Stage and Route of Administration, H2 2012 290
Assessment by Molecule Type, H2 2012 291
Assessment by Stage and Molecule Type, H2 2012 292

Note: Product cover images may vary from those shown

RELATED PRODUCTS

  • Psoriasis - Pipeline Review, H2 2012 - Product Thumbnail Image Psoriasis - Pipeline Review, H2 2012

    Psoriasis - Pipeline Review, H2 2012

    • Language: English
    • Published: August 2012
    FROM
  • Male Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image Male Cancer - Pipeline Review, H2 2012

    Male Cancer - Pipeline Review, H2 2012

    • Language: English
    • Published: August 2012
    FROM
  • Non-Small Cell Lung Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image Non-Small Cell Lung Cancer - Pipeline Review, H2 2012

    Non-Small Cell Lung Cancer - Pipeline Review, H2 2012

    • Language: English
    • Published: September 2012
    FROM
  • Glioma - Pipeline Review, H2 2012 - Product Thumbnail Image Glioma - Pipeline Review, H2 2012

    Glioma - Pipeline Review, H2 2012

    • Language: English
    • Published: October 2012
    FROM
  • Lung Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image Lung Cancer - Pipeline Review, H2 2012

    Lung Cancer - Pipeline Review, H2 2012

    • Language: English
    • Published: October 2012
    FROM
  • Breast Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image Breast Cancer - Pipeline Review, H2 2012

    Breast Cancer - Pipeline Review, H2 2012

    • Language: English
    • Published: October 2012
    FROM
  • Pain - Pipeline Review, H2 2012 - Product Thumbnail Image Pain - Pipeline Review, H2 2012

    Pain - Pipeline Review, H2 2012

    • Language: English
    • Published: November 2012
    FROM
  • Gastric Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image Gastric Cancer - Pipeline Review, H2 2012

    Gastric Cancer - Pipeline Review, H2 2012

    • Language: English
    • Published: November 2012
    FROM
  • Leukemias - Pipeline Review, H2 2012 - Product Thumbnail Image Leukemias - Pipeline Review, H2 2012

    Leukemias - Pipeline Review, H2 2012

    • Language: English
    • Published: December 2012
    FROM
  • Blood Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image Blood Cancer - Pipeline Review, H2 2012

    Blood Cancer - Pipeline Review, H2 2012

    • Language: English
    • Published: December 2012
    FROM

Our Clients

Our clients' logos